ArticleClinical and experimental gastroenterology2026

Long-Term Safety of Ontamalimab in Patients with Moderate to Severe Inflammatory Bowel Disease.

Geert D'Haens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.